BioSpace News Archive

Coya Therapeutics, Inc. (“Coya”), a privately held clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced its participation in the annual Neuro & Ophthalmology Conference hosted by B. Riley Securities, a leading full-service investment bank and subsidiary of B. Riley Financial, on April 27-28th 2022.

Amryt is pleased to announce that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the approval of Filsuvez® in the European Union for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa in patients 6 months and older.

Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of Getlabs for Labcorp, an innovative health care service that combines Labcorp’s diagnostic tests with Getlabs phlebotomy service to conveniently test consumers in the comfort of their own homes.

Royal Philips, a global leader in health technology, announced that its subsidiary Philips Respironics is notifying customers of its V60/V60 Plus and V680 ventilators about a potential issue with the electrical circuit in these ventilators that controls the 35V power supply to the ventilator and alarm.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Virtual Neuro and Ophthalmology Conference, April 27-28, 2022.

Sanger sequencing is one of the oldest DNA sequencing methods carried out using oligonucleotide primers and chain termination.

According to Emergen Research, the global nanorobotics market size was USD 6.12 billion in 2020 and is expected to reach USD 14.03 billion in 2028 and register a revenue CAGR of 10.9% during the forecast period, 2021-2028.

Increasing prevalence of hair loss among individuals across the globe, rising demand for efficient treatment modalities, and growing number of clinical trials are some key factors expected to drive market growth.

Rising prevalence of infectious diseases, increasing investments in R&D activities, and growing application of antibiotics in development of bacterial and viral vaccines are key factors expected to drive market revenue growth.

Rising incidence of arthritis and knee injuries, technological advancements in arthroscopic devices and procedures, and growing number of product launches are some factors expected to drive market revenue growth.